FRACTYL HEALTH, INC.
Close on Oct 19, 2026
- Market cap
- $218.94M
- P/E (TTM)
- –
- Dividend yield
- –
About Fractyl Health
Surgical & Medical Instruments & Apparatus, SIC 3841
Fractyl Health, Inc. is a metabolic therapeutics company focused on developing treatments for metabolic diseases, including type 2 diabetes and obesity. The company's lead product candidate is Revita, an outpatient procedural medical device designed to remodel the duodenal mucosal lining via duodenal mucosal resurfacing. In addition, Fractyl is advancing its Rejuva gene therapy platform, which includes lead candidate RJVA-001, targeting metabolic pathways to provide sustained disease-modifying benefits for patients.
The company operates primarily in the United States, conducting research, development, and clinical evaluation across domestic and international clinical sites. Its facilities include office and laboratory space leased in Massachusetts, supported by in-house and contract manufacturing capabilities. Fractyl Health maintains its principal executive offices in Burlington, Massachusetts.
Summary of the business section of Fractyl Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- FRACTYL HEALTH, INC.
- Founded
- 2010
- Headquarters
- Burlington, MA
- Address
- 3 Van De Graaff Drive, Suite 200 01803
- Phone
- (781) 902-8800
- Website
- www.fractyl.com
- Employees
- 100, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- GUTS
- Exchange
- Nasdaq
- IPO date
- Feb 2, 2024
- Shares outstanding
- 159M, Aug 4, 2026
- Public float
- $49.60M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-12 reverse, Oct 5, 2026
- SEC CIK
- 1572616
- CUSIP
- 35168W202
- ISIN
- US35168W2026
- EIN
- 27-3553477
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Harith Rajagopalan | Chief Executive Officer, Director | 1,143,537 |
| Weber Lara Smith | Chief Financial Officer | 20,000 |
| Jay David Caplan | President, Chief Product Off. | 631,160 |
| Sarah Toomey | General Counsel | – |
| Timothy Kieffer | Chief Scientific Officer | – |
| Lisa Davidson | Chief Financial Officer | 7,525 |
| William Bradley | Director | 149,138 |
| Ajay Royan | Director | 5,201,202 |
| Ian Sheffield | Director | 35,000 |
| Christopher Charles Thompson | Director | – |
| Samuel Conaway | Director | 0 |
| Clive Meanwell | Director | 277,890 |
| Marc Elia | Director | – |
| Kelly Ann Barnes | Director | 31,000 |
| Amy W. Schulman | Director | 8,550 |
Employees
Headcount reported in annual reports
“As of March 1, 2026, we have 100 full-time employees, 73 of whom are dedicated to research and development, and 14 of whom hold doctorate degrees (i.e., Ph.D., Pharm.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 11, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 17, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 2, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 29, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 19, 2020 | Name change | Name changed from Fractyl Laboratories Inc. to FRACTYL HEALTH, INC. |